Innate Immunity Activator Protein (C1ORF106) (AA 236-663) anticorps
Cet anticorps anti-Innate Immunity Activator Protein est un anticorps Polyclonal produit chez le Lapin, détectant Innate Immunity Activator Protein dans ELISA et WB. Convient pour Humain.
Aperçu rapide pour Innate Immunity Activator Protein (C1ORF106) (AA 236-663) anticorps (ABIN7600790)
Antigène
Innate Immunity Activator Protein (C1ORF106)
Reactivité
Humain
Hôte
Lapin
Clonalité
Polyclonal
Conjugué
Inconjugué
Application
ELISA, Western Blotting (WB)
Épitope
AA 236-663
Fonction
Anti-INAVA Antibody
Attributs du produit
Anti-INAVA Antibody (ABIN7600790). Tested in WB, ELISA applications. This antibody reacts with Human. This is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications.
Purification
Immunogen affinity purified.
Immunogène
E.coli-derived human INAVA recombinant protein (Position: Q236-V663). Human INAVA shares 85.3% amino acid (aa) sequence identity with mouse INAVA.
At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.
Antigène
Innate Immunity Activator Protein (C1ORF106)
Autre désignation
INAVA
Sujet
INAVA, sometimes referred to as hypothetical protein LOC55765, is a protein of unknown function that in humans is encoded by the INAVA gene. Expressed in peripheral macrophages and intestinal myeloid-derived cells, is required for optimal PRR (pattern recognition receptor)-induced signaling, cytokine secretion, and bacterial clearance. Upon stimulation of a broad range of PRRs (pattern recognition receptor) such as NOD2 or TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9, associates with YWHAQ/14-3-3T, which in turn leads to the recruitment and activation of MAP kinases and NF-kappa-B signaling complexes that amplifies PRR-induced downstream signals and cytokine secretion (PubMed:28436939). In the intestine, regulates adherens junction stability by regulating the degradation of CYTH1 and CYTH2, probably acting as substrate cofactor for SCF E3 ubiquitin-protein ligase complexes. Stabilizes adherens junctions by limiting CYTH1-dependent ARF6 activation (PubMed:29420262).